Hyper (XKRX:065650) Accounts Payable : ₩0 Mil (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Hyper Accounts Payable?

Hyper's Accounts Payable for the quarter that ended in Mar. 2024 was ₩0 Mil.

Hyper's quarterly Accounts Payable increased from Sep. 2023 (₩942 Mil) to Dec. 2023 (₩971 Mil) but then declined from Dec. 2023 (₩971 Mil) to Mar. 2024 (₩0 Mil).

Hyper's annual Accounts Payable declined from Dec. 2021 (₩1,300 Mil) to Dec. 2022 (₩1,069 Mil) and declined from Dec. 2022 (₩1,069 Mil) to Dec. 2023 (₩971 Mil).

Hyper Accounts Payable Historical Data

The historical data trend for Hyper's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyper Accounts Payable Chart

Hyper Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

545.03

1,154.50

1,299.50

1,069.32

971.03

Hyper Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															1,315.16	927.62	941.89	971.03	-

Hyper Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Hyper Accounts Payable Related Terms

Thank you for viewing the detailed overview of Hyper's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyper (XKRX:065650) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyper Corporation Inc (XKRX:065650) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Woolim A-1401, 583, Yangcheon-ro, Gangseo-gu, Seoul, KOR, 07547

Website

http://www.medifron.com

Medifron DBT Co Ltd is a Korean clinical stage biopharmaceutical company. The company is focused on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.

Hyper (XKRX:065650) Headlines

No Headlines